中文
EN
R&D and Innovation
R&D and Innovation
News Center
Innovation Strategy
Innovation has been embedded in Viwit’s DNA since its inception. It is the fundamental driving force behind our evolution from an industry follower to a scientific explorer. Guided by our mission of “Innovation for a better life,” we translate innovation from a concept into executable and iterative strategies and practices.
Our innovation journey follows a clear and resolute path of industrial upgrading. Starting from our core technological foundation in chiral borane chemistry, we have progressively established a series of differentiated technology platforms, including chiral drug technologies and modified/controlled-release formulation technologies. The synergistic evolution of these platforms has supported the continuous advancement of our business—from chiral intermediates, to specialty APIs, to high-end generic drugs and 505(b)2 drugs—and ultimately toward the development of truly innovative NCE drugs driven by clinical value.
Today, Viwit’s innovation has entered a new stage defined by “driven by insight and science”. In addition to pursuing frontier exploration, we leverage our mature industrial capabilities to provide critical support for the translation of cutting-edge science:
Radiopharmaceutical R&D and Manufacturing Platform:
As a strategic pillar in the field of nuclear medicine, this platform provides essential support from research to commercialization. Leveraging the Shandong Provincial Key Laboratory for Radionuclide Drug Conjugates R&D, the corresponding Engineering Research Center, and our Class B radiation safety qualification, we have established dedicated radiopharmaceutical R&D laboratories and production lines. We focus on delivering high-quality CMC research, process scale-up, and manufacturing services, enabling our partners’ breakthroughs in target identification and molecular design to be efficiently and compliantly translated into drug products suitable for clinical trials. Our support for VitsGen Therapeutics is a representative example of the success of this platform.
Innovative Biologics Development Platform:
With a forward-looking strategy and leveraging the strengths of our targeted molecule MAP drug design platform, we are advancing new therapeutic modalities such as targeted gene therapies and (in vivo) cell therapies. We are actively building core technologies in frontier areas of biopharmaceutical innovation and, through continuous technological upgrades, improving accessibility to treatments for cancer immunotherapy, autoimmune diseases, and genetic disorders.
AI-Empowered Drug Design and Development Platform:
By integrating computational science with biological science, and combining generative AI–based drug design with computer-aided drug design in a complementary manner, we accelerate the discovery and optimization of clinical candidates, improving both R&D efficiency and success rates.
This model—integrating deep, end-to-end industrialization capabilities with frontier scientific exploration—demonstrates our strength in enabling the translation of major innovations. It highlights Viwt’s critical role as a mature R&D and manufacturing platform in transforming scientific concepts into real-world products within complex and cutting-edge fields.
Our unwavering commitment to innovation has been internalized into systemic capabilities and validated by a quality system compliant with GMP standards in China, the United States, and Europe, as well as by our proven ability to achieve regulatory approvals in both China and the United States. Looking ahead, we will continue to build on science as our foundation and robust industrial capabilities as our support, advancing ever deeper along the path of innovation to deliver transformative healthcare solutions to the world.